Enrollment complete

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Clinicaltrials.gov Identifier: 

nct06269133

Trial details

Trial date:
February 21, 2024 - March 31, 2027
Phase:  N/A
Birth sex
Male and female gender symbols.
Age range
18 Years and Older
Accepts healthy volunteers
No
Condition(s) being studied: 

Advanced Non-small Cell Lung Cancer

What is the type of trial? 

Observational

What is the trial testing? 

REGN2810

How many people are being enrolled? 

1000

Trial summary

This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.

Trial locations

0 location(s)